The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2025 | FAME: metformin and fasting-mimicking diet in LKB1-inactive NSCLC
Mario Occhipinti, MD, PhD, Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy, discusses the Phase II FAME trial (NCT03709147), which assessed metformin with or without a fasting-mimicking diet alongside first-line chemo-immunotherapy in advanced LKB1-inactive non-small cell lung cancer (NSCLC). Despite early closure due to low recruitment, results suggest a potential survival benefit in patients with Stk11 mutations. Findings highlight the role of metabolic interventions in addressing treatment-resistant NSCLC, warranting further investigation into glucose deprivation strategies to enhance therapeutic efficacy. This interview took place at the European Lung Cancer Congress (ELCC) 2025 in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
